He & She MD vs Ro
Two GLP-1 desks, one scoreboard. We put He & She MD and Ro head-to-head on the published Brief Score — the same six factors, scored the same way.
The verdict
Ro takes this head-to-head.
Ro scores 87 to 77 on our six-factor Brief Score — A heavyweight platform with brand-name access and a polished experience — but it keeps compounded pricing off the record.
That doesn't make He & She MD a bad call — it's best for readers who want a published glp-1 price ladder, injectable or oral, and are willing to prepay a term to reach the low rate. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| He & She MD | Ro | |
|---|---|---|
| Brief Score | 77/100 (C) | 87/100 (B+) |
| Semaglutide | From $199/mo (month to month, compounded; every lower rate is a prepaid term) | Not disclosed |
| Tirzepatide | From $299/mo (month to month, compounded; every lower rate is a prepaid term) | Not disclosed |
| Coverage | All states except Louisiana (GLP-1) | Multi-state |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
| On the tracker | Newnew to the tracker, no prior reading | Stableprice stable |
He & She MD: New to the tracker on 1 August 2026. At our first reading we filed From $139/mo as the headline and called it a starting-dose rate; re-read 2026-08-14 against the provider's own plan page, $139 is the SIX-MONTH SEMAGLUTIDE rate ($834 charged up front) and the month-to-month rate is $199; there is no earlier reading of ours to compare it against yet.
Ro: Brand-name access and insurance navigation, but compounded pricing stays off the record.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.